Comparison of the Efficacy and Safety of Irbesartan and Olmesartan in Patients With Hypertension (EARTH Study)

Abstract

Fifty-four patients were randomly divided into irbesartan and olmesartan groups. Blood pressure (BP) was significantly decreased in all patients at 12 weeks. In particular, BP in patients who initially received irbesartan showed significant reductions. The equality of variance of BP in the irbesartan group was significantly smaller than that in the olmesartan group at 12 weeks. Blood concentrations of adiponectin were significantly increased in the irbesartan group at 12 weeks. Log [pentraxin-3] in the irbesartan group were significantly decreased. In conclusion, the ability of irbesartan to reduce BP is comparable to that of olmesartan with equivalent safety.

Comparison of the Efficacies of Irbesartan and Olmesartan after Successful Coronary Stent Implantation

“…Since the ability of irbesartan to reduce BP was equal to that of olmesartan, the ability of a medium dose of irbesartan (100 mg/day) to reduce BP may be similar to that of a medium dose of olmesartan (20 mg/day). We previously reported that the ability of irbesartan to reduce BP after treatment for 12 weeks is at least comparable to that of olmesartan with equivalent safety (7). The present study also showed a similar result after more long-term treatment for approximately eight months.…”

“…Irbesartan was also associated with a lower variance of SBP at eight months. There are several possible explanations for this difference in the variance of SBP, which we have discussed in our previous report (7). First, the unique binding behavior of irbesartan is different from that of olmesartan.…”

“…The in-stent late loss and decrease in % diameter stenosis (DS) under treatment with valsartan are significantly lower than those achieved with losartan as assessed by quantitative coronary angiography (QCA) after six months in patients with acute myocardial infarction (6). We also previously compared the efficacy and safety of irbesartan to that of olmesartan in patients with hypertension (HT) (7). Although the BP reduction observed in the irbesartan group was similar to that observed in the olmesartan group, the equality of variance of BP (i.e., the intragroup standard deviation of BP) in the irbesartan group was significantly smaller than that observed in the olmesartan group (7).…”

“…We also previously compared the efficacy and safety of irbesartan to that of olmesartan in patients with hypertension (HT) (7). Although the BP reduction observed in the irbesartan group was similar to that observed in the olmesartan group, the equality of variance of BP (i.e., the intragroup standard deviation of BP) in the irbesartan group was significantly smaller than that observed in the olmesartan group (7). In addition, the blood concentrations of adiponectin were significantly increased in the irbesartan group, and a marker of inflammation, pentraxin (PTX)-3, the was significantly decreased in the irbesartan group.…”

Efficacy and safety of combination therapy of high-dose losartan and hydrochlorothiazide in patients with hypertension

“…20 Telmisartan may be useful in hypertensive patients with insulin resistance or DM. 21 Nonetheless, in this study, the levels of HbA1c and FBS did not change at three months after a changeover from high-dose telmisartan and HTCZ to high-dose losartan and HTCZ.…”